阿昔替尼联合帕博利珠单抗治疗晚期肉瘤及腺泡状软组织肉瘤的II期试验
BACKGROUND: VEGF promotes an immunosuppressive microenvironment and contributes to immune checkpoint inhibitor resistance in cancer.…
要点
- 常见3-4级治疗相关不良事件包括高血压和自身免疫毒性,各占15%。
核心结论
- 阿昔替尼联合帕博利珠单抗在晚期肉瘤患者中具有可控的毒性和初步抗肿瘤活性,尤其在腺泡状软组织肉瘤患者中,值得在随机对照试验中进一步研究。
研究设计与样本
- 单中心、单臂、II期试验,在美国迈阿密一家三级学术医疗中心开展,患者来自全美及国际。
- 纳入33例年龄≥16岁、组织学确诊的晚期或转移性肉瘤患者(含腺泡状软组织肉瘤),ECOG评分0-1,既往至少一线系统治疗后进展(除非无标准治疗或患者拒绝)。
- 前5例为导入队列,接受阿昔替尼5 mg口服每日两次和帕博利珠单抗200 mg静脉输注(第8天及每3周一次,周期6周,最长2年);后续患者接受阿昔替尼剂量递增(2-10 mg)联合固定剂量帕博利珠单抗。
- 主要终点为3个月无进展生存率,所有患者可评估生存和安全性分析。
主要发现
- 2016年4月19日至2018年2月7日,36例患者接受资格评估,33例(92%)入组并接受治疗,其中12例(36%)为腺泡状软组织肉瘤。
- 最常见的3级或4级治疗相关不良事件包括高血压(5例[15%])、自身免疫毒性(5例[15%])、恶心或呕吐(2例[6%])和癫痫发作(2例[6%])。
- 7例(21%)患者发生严重治疗相关不良事件,包括自身免疫性结肠炎、转氨酶升高、气胸、咯血、癫痫发作和高甘油三酯血症;无治疗相关死亡。
关键数值与推荐
- 3级或4级治疗相关不良事件:高血压5例(15%)、自身免疫毒性5例(15%)、恶心或呕吐2例(6%)、癫痫发作2例(6%)。
- 严重治疗相关不良事件发生于7例(21%)患者。
临床怎么用
- 对于晚期肉瘤患者,尤其是腺泡状软组织肉瘤,阿昔替尼联合帕博利珠单抗可作为潜在治疗选择,但需关注高血压、自身免疫毒性等不良反应。
- 治疗期间应监测血压、自身免疫相关症状及神经系统事件(如癫痫发作)。
局限性
- 单中心、单臂设计,样本量较小(33例),结果需随机对照试验验证。
- 腺泡状软组织肉瘤亚组样本量小(12例),置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: VEGF promotes an immunosuppressive microenvironment and contributes to immune checkpoint inhibitor resistance in cancer. We aimed to assess the activity of the VEGF receptor tyrosine-kinase inhibitor axitinib plus the anti-PD-1 immune checkpoint inhibitor pembrolizumab in patients with sarcoma. METHODS: This single-centre, single-arm, phase 2 trial was undertaken at a tertiary care academic medical centre in Miami, FL, USA, and participants were recruited from all over the USA and internationally. Patients were eligible if they were aged 16 years or older, and had histologically confirmed advanced or metastatic sarcomas, including alveolar soft-part sarcoma (ASPS); measurable disease with one site amenable to repeated biopsies; an ECOG performance status of 0-1; and progressive disease after previous treatment with at least one line of systemic therapy (unless no standard treatment existed or the patient declined therapy). The first five patients were enrolled in a lead-in cohort and were given axitinib 5 mg orally twice daily and pembrolizumab 200 mg intravenously for 30 min on day 8 and every 3 weeks for cycles of 6 weeks for up to 2 years. Thereafter, patients received escalating doses of axitinib (2-10 mg) plus flat dose pembrolizumab according to the schedule above. The primary endpoint was 3-month progression-free survival. All patients were evaluable for survival and safety analyses. This study is registered with ClinicalTrials.gov, number NCT02636725, and is closed to accrual. FINDINGS: Between April 19, 2016, and Feb 7, 2018, of 36 patients assessed for eligibility, 33 (92%) were enrolled and given study treatment (intention-to-treat population and safety population), 12 (36%) of whom had ASPS. With a median follow-up of 14·7 months (IQR 10·1-19·1), 3-month progression-free survival for all evaluable patients was 65·6% (95% CI 46·6-79·3). For patients with ASPS, 3-month progression-free survival was 72·7% (95% CI 37·1-90·3). The most common grade 3 or 4 treatment-related adverse events included hypertension (five [15%] of 33 patients), autoimmune toxicities (five [15%]), nausea or vomiting (two [6%]), and seizures (two [6%]). Serious treatment-related adverse events occurred in seven (21%) patients, including autoimmune colitis, transaminitis, pneumothorax, haemoptysis, seizures, and hypertriglyceridemia. There were no treatment-related deaths. INTERPRETATION: Axitinib plus pembrolizumab has manageable toxicity and preliminary activity in patients with advanced sarcomas, particularly patients with ASPS, warranting further investigation in randomised controlled trials. FUNDING: Merck, Pfizer, American Cancer Society, and Sylvester Comprehensive Cancer Center.
引用
- Wilky BA, Trucco MM, Subhawong TK, et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol. 2019. PMID: 31078463. doi:10.1016/S1470-2045(19)30153-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。